Drugs / NEGALSTOBART
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05088967 | Dec 2021 | non-small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05039658 | Sep 2021 → Jul 2022 | diffuse large B-cell lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05026593 | Sep 2021 → Feb 2023 | small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04085185 | Dec 2019 → Dec 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06494943 | Jun 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05572463 | Nov 2022 → Jun 2027 | cutaneous melanoma | Innovent Biologics (Suzhou) Co. Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT06078657 | Oct 2023 → Oct 2024 | esophageal squamous cell carcinoma | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-06-05 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting innoventbio.com ↗
There were no treatment-related deaths. |
| 2022-12-09 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress innoventbio.com ↗
For safety results, the most common treatment related adverse events (TRAEs) ≥ grade 3 were decreased neutrophil count (30.0%) and decreased white blood cell count (20.0%). |
| 2022-06-04 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting innoventbio.com ↗
6 patients achieved partial response (PR); the objective response rate (ORR) was 15.4% and the disease control rate (DCR) was 64.1%. |
| 2021-06-07 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Release the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021 innoventbio.com ↗
The efficacy signal and safety profile we see with IBI110 in this study is exciting. |
All press releases naming this drug 5 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEGALSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314852 ↗ |
| Known as | BI110 | “BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.” NCT05039658 ↗ |
| Known as | IBI110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06078657 ↗ |
| Action | Inhibit | “Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab” PMID 39736787 ↗ Dec 2024 |
| Modality | Monoclonal antibody | “IBI110 (anti-lymphocyte activation gene 3 \[LAG-3\] monoclonal antibody)” NCT05026593 ↗ |
| Route | Intravenous | “IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle” NCT04085185 ↗ |
| Target | LAG3 | “anti-lymphocyte activation gene-3 (LAG-3) antibody IBI110” PMID 41591537 ↗ Jan 2026 |